Group 1 - Seasonal influenza impacts approximately 1 billion people globally each year, with 3 to 5 million cases developing into severe illness and 290,000 to 650,000 deaths due to influenza-related respiratory diseases [1] - The domestic influenza treatment drug market is currently dominated by Dongyangguang Pharmaceutical with Oseltamivir, but new players are rapidly emerging since 2025 [1] - Zhengxiang Pharmaceutical is seeking to list on the Hong Kong Stock Exchange, having submitted its application on January 30, with CICC as its sole sponsor [2][4] Group 2 - Zhengxiang Pharmaceutical's antiviral drug, Marcilosavir, has already been approved for market release, distinguishing it from most other 18A companies [3] - The company was founded in 2018 and has undergone multiple rounds of financing, raising a total of 872 million RMB, with a post-investment valuation of 2.48 billion RMB as of January 2026 [4][5] - The company has a drug portfolio that includes six assets, with Marcilosavir being the core product, which is a new generation antiviral targeting influenza [10][12] Group 3 - The global market for influenza treatment and prevention drugs is projected to reach $4.8 billion by 2024, with China contributing $1.7 billion [16] - The Chinese market for antiviral drugs is expected to grow to 13.6 billion RMB by 2035, with PA inhibitors and other antiviral drugs accounting for 13 billion RMB [17] - Marcilosavir faces competition from several established products, including Roche's Baloxavir and others, with pricing set at 222 RMB per box, which is higher than some competitors [20] Group 4 - Zhengxiang Pharmaceutical reported zero revenue for 2024 and 400,000 RMB for the first nine months of 2025, primarily from regulatory support services for Marcilosavir [23] - The company incurred losses of approximately 145 million RMB for both 2024 and the first nine months of 2025, totaling around 290 million RMB in cumulative losses [23] - The company collaborates with a national CSO, Jichuan Pharmaceutical, to enhance market share through its established distribution network [24] Group 5 - The company has a total of 52 R&D personnel, with significant expenditures on drug development, amounting to 100 million RMB and 81.6 million RMB in R&D costs for the respective reporting periods [23] - As of November 2025, the company had cash and cash equivalents of 523 million RMB and term deposits of 141 million RMB [27] - The overall cash flow from operating activities showed a net outflow of 1.06 billion RMB for 2024, indicating financial challenges [28]

征祥医药收入高度依赖去年7月获批的流感新药玛硒洛沙韦片，但目前该产品尚未贡献主要收入。其面 临的市场竞争激烈——青峰药业、众生药业的流感药物已先一步获批并进入医保，健康元药业的相关产 品也于去年12月获批。作为后来者，征祥医药亟须突出市场重围。在此背景下，赴港上市成为征祥医药 缓解债务压力、为后续发展寻求资金支持的关键步骤。 背负巨债的征祥医药（南京）集团有限公司（以下简称"征祥医药"），正将其未来押注于一款流感新 药，并由此启动港股上市进程。近日，征祥医药向港交所递交招股书，拟港股上市。招股书显示，2024 年及2025年前三季度，征祥医药营收合计不足40万元，同期亏损累计近3亿元，经营活动现金流持续为 负。截至2025年9月末，负债净额攀升至9.56亿元，资产负债率达415.84%。 在定价策略上，玛硒洛沙韦片的定价与罗氏的玛巴洛沙韦一致，均为222元/盒。相比之下，同为PA抑制 剂的青峰药业的玛舒拉沙韦片和健康元药业的玛帕西沙韦定价分别为175元和198元。征祥医药的产品在 性价比方面并不占优势。 不仅如此，根据京东平台流行性感冒用药排行榜数据，玛巴洛沙韦及磷酸奥司他韦依然占据销量的绝对 主导地位。而在 ...

Core Insights - The article discusses the recent developments in the pharmaceutical industry, particularly focusing on the approval of innovative drugs and their market implications [12][15]. Market Performance - The pharmaceutical and biotechnology indices experienced a slight decline, with the medical biotechnology index down by 0.29%, outperforming the Shanghai Composite Index by 0.05 percentage points [5]. - The Hang Seng Healthcare Index fell by 2.26%, while the Hong Kong innovative drug ETF decreased by 2.18% [5]. Innovative Drug Approvals - Eight innovative drugs received approval last week, including: - **Fitusiran** for hemophilia A or B [11]. - **库莫西利** (Kumosili), a CDK2/4/6 inhibitor for HR+/HER2- breast cancer, which is expected to address resistance issues seen with existing treatments [12][14]. - **玛帕西沙韦** (Marpasiwe), an antiviral for influenza, showing significant efficacy in clinical trials [15]. Clinical Trials and Research - The article highlights ongoing clinical trials, including a significant Phase III trial for **库莫西利**, which demonstrated a median progression-free survival (PFS) of 16.62 months, extending PFS by 9.16 months compared to the control group [14]. - A total of 96 new clinical trial registrations were disclosed, with 30 trials in Phase II or higher [7]. Industry Trends - The innovative drug sector remains a key investment focus, with ongoing business development activities and cross-border transactions indicating strong confidence in domestic innovation capabilities [6]. - The global market for CDK4/6 inhibitors is projected to reach approximately $24 billion, driven by increasing indications for early-stage breast cancer [12]. Challenges - The article notes that resistance to CDK4/6 inhibitors remains a significant challenge, with about 20% of HR+ breast cancer patients showing primary resistance to endocrine therapy [12].

Core Viewpoint - The article highlights the rapid approval and commercialization of domestic influenza antiviral drugs in China, suggesting that 2025 may be regarded as the "Year of Domestic Influenza Innovation Drugs" due to the continuous improvement of China's pharmaceutical innovation capabilities [1]. Group 1: Commercialization of Domestic Influenza Drugs - From March to July 2025, three domestic antiviral drugs (Mashu Lashawei Tablets, Angladwei Tablets, and Mase Luoshawei Tablets) were approved for market entry, with two more (Madu Nuo Shawei and Mapaqi Shawei) completing clinical trials and applying for approval [3][4]. - Sales of these domestic innovative drugs are steadily increasing, indicating recognition of their efficacy and safety [3]. Group 2: Market Potential and Competition - The global seasonal influenza cases are estimated at around 1 billion annually, with 3 to 5 million severe cases, indicating a vast market for antiviral drugs [4]. - The Chinese antiviral drug market is projected to grow at a compound annual growth rate (CAGR) of 20.2% from 2024 to 2028, potentially reaching 26.9 billion yuan by 2028 [4]. - Despite strong demand, the domestic market has been dominated by imported drugs, with Oseltamivir holding over 80% market share in 2023 [4]. Group 3: Factors Driving Innovation - The rise of domestic influenza innovative drugs is attributed to a combination of policy support, technological advancements, and capital investment, marking a significant transformation in the industry [6]. - The National Medical Products Administration has implemented measures to accelerate drug approval processes, resulting in a rapid increase in the number of approved innovative drugs, with 48 approved in 2024 and 43 in the first half of 2025, a 59% year-on-year increase [7]. - The Chinese biopharmaceutical industry is developing rapidly, with the total value of biopharmaceutical business development (BD) transactions exceeding 100 billion USD in 2025, expected to reach 265.9 billion USD by 2030, with a CAGR of 31.3% from 2024 to 2030 [7]. Group 4: Market Sentiment and Future Outlook - Recent catalysts in the innovative drug sector, including the results of national health insurance negotiations and international conferences, are expected to improve market sentiment [8]. - The article suggests that despite recent adjustments in the sector, the trend of "innovation + internationalization" remains strong, with potential for recovery in the innovative drug sector [8].

Core Insights - Multiple domestic innovative antiviral drugs for influenza have been approved this year, leading to significant market attention, with 2025 being referred to as the "Year of Domestic Influenza Innovative Drugs" [1][10] - The rapid progress in domestic influenza innovative drugs reflects the continuous improvement of China's pharmaceutical innovation capabilities [1][10] Group 1: Market Dynamics - From March to July 2025, three antiviral drugs (Mashurashave tablets, Angladive tablets, and Maseiluo tablets) were approved, with two more (Madiroshave and Mapashirashave) completing clinical trials and applying for market entry [2][11] - The sales of these domestic innovative drugs are steadily increasing, indicating recognition of their efficacy and safety [2][11] - The global influenza antiviral market is projected to grow significantly, with China's market expected to reach 26.9 billion yuan by 2028, growing at a compound annual growth rate (CAGR) of 20.2% from 2024 to 2028 [3][12] Group 2: Competitive Landscape - The domestic new drugs are not mere copies of imported drugs but have undergone targeted optimizations, such as reducing drug resistance risks and improving safety for pediatric use [2][11] - Despite strong demand, the Chinese influenza drug market has been dominated by imported drugs, with Oseltamivir holding over 80% market share in 2023 [3][12] - The acceleration of domestic new drug approvals is expected to lead to rapid sales growth, enhancing company performance [3][12] Group 3: Policy and Industry Support - Recent regulatory reforms by the National Medical Products Administration have improved drug approval efficiency, with 48 innovative drugs approved in 2024, ranking second globally [7][16] - The Chinese biopharmaceutical industry is rapidly developing, with the total value of innovative drug business development (BD) transactions exceeding 100 billion USD in 2025, projected to reach 265.9 billion USD by 2030 [7][16] Group 4: Future Outlook - The overall industry sentiment is expected to improve as positive catalysts continue to emerge, with recent developments in innovative drug insurance negotiations and international conferences [8][17] - Investors are encouraged to consider ETFs that cover high-quality innovative pharmaceutical companies in both Hong Kong and A-shares to mitigate individual stock risks and capitalize on the opportunities in China's innovative drug sector [8][17]

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology industry [1] Core Insights - The GLP-1 class of drugs has become a revolutionary therapy in the weight loss field, transitioning from an "adjunctive" role to a "core medication" status, significantly improving metabolic indicators while effectively reducing weight [19][20] - Multiple companies have disclosed promising weight loss data, with a focus on domestic companies such as Federated Pharmaceutical, Lepu Medical, and Greeley Pharmaceuticals [2][19] - The report highlights the potential of oral small molecule GLP-1 drugs, with significant clinical data from companies like Greeley Pharmaceuticals and Structure Therapeutics [21][22] Summary by Sections Investment Highlights - The report emphasizes the growth potential in the weight loss drug market, driven by drugs like Semaglutide and Tirzepatide, with notable clinical results from various companies [2][19] - The report suggests monitoring the development of domestic small nucleic acid drugs, which have shown promising results in reducing visceral fat and increasing lean body mass [2] Sub-industry Rankings - The report ranks sub-industries in the following order: Innovative Drugs > Research Services > CXO > Traditional Chinese Medicine > Medical Devices > Pharmacies [3][12] - Specific stock recommendations include Federated Pharmaceutical, Lepu Medical, and Greeley Pharmaceuticals from the GLP perspective, and companies like 3SBio, Kintor Pharmaceutical, and Innovent Biologics from the PD1/VEGF dual antibody perspective [3][15] Market Performance - The A-share pharmaceutical index has shown a year-to-date increase of 14.65%, while the Hang Seng Biotechnology Index has increased by 77.09% [11] - The report notes that the medical services sector has seen a price increase of 1.67%, while other sectors like chemical pharmaceuticals and medical devices have experienced declines [11] Clinical Development Updates - Greeley Pharmaceuticals' ASC30 achieved a 7.7% weight reduction in a 13-week study, while Structure Therapeutics' Aleniglipron showed a 15.3% reduction in a 36-week study [21][22] - The report highlights the competitive landscape of oral GLP-1 drugs, with Greeley's ASC30 demonstrating superior weight loss effects compared to Eli Lilly's Orforglipron [23]

Core Insights - The flu season of 2025 is reported to be more severe than the past three years, with increased cases of flu-like illnesses (ILI) in both northern and southern China [3][4][12] - There is a notable shortage of flu medications, particularly the children's version of the antiviral drug Marbofloxacin, leading to increased demand and stockouts in pharmacies [4][8][12] - Hospitals remain the primary choice for parents seeking treatment for their children, with a significant increase in pediatric flu patients reported [9][12] Summary by Category Flu Season Severity - The percentage of flu-like illness cases reported by sentinel hospitals in southern provinces was 6.7%, while northern provinces reported 7.0%, both higher than the previous week and the same period in 2022, 2023, and 2024 [3][4] Medication Availability - Pharmacies are experiencing shortages of flu medications, with some lacking the new antiviral drug "Sufuda" (generic name: Marbofloxacin) entirely, while traditional antiviral drugs like Oseltamivir are still available [4][8] - The children's version of Marbofloxacin is particularly in high demand, with reports indicating it is more sought after than other flu medications [8][14] Hospital Preference - Parents express a strong preference for hospitals over pharmacies for flu treatment, citing trust in clinical doctors [9][12] - Roche, the manufacturer of "Sufuda" and "Oseltamivir," has increased supply to hospitals, with the overall supply of "Sufuda" reportedly three times that of the previous year [9][12] Pediatric Medication Insights - Oseltamivir is widely used for children, with a broader age indication compared to Marbofloxacin, which is limited to children aged 5 and above [12][14] - The single-dose administration of Marbofloxacin is appealing to parents, but its availability in hospitals is limited, leading to increased purchases from pharmacies [14][16] Market Dynamics - The market for pediatric single-dose flu medications is expected to become more competitive as several domestic pharmaceutical companies are developing similar products [16] - Recent approvals for new pediatric flu medications are anticipated to challenge the current market dominance of Marbofloxacin in the coming years [16]

Core Viewpoint - The flu season of 2025 is reported to be more severe than in the past three years, with increased cases of flu-like illnesses (ILI) across both northern and southern regions of China, leading to a shortage of specific flu medications, particularly for children [1][3][11]. Summary by Sections Flu Season Severity - The latest report from the Chinese Center for Disease Control and Prevention indicates that from November 10 to 16, 2025, the ILI percentage in southern provinces was 6.7% and in northern provinces was 7.0%, both higher than the previous week and the same period in 2022, 2023, and 2024 [3][11]. Medication Shortages - Many pharmacies are experiencing shortages of flu medications, particularly the children's version of the antiviral drug "速福达" (Mabalaoshuwei). Traditional antiviral drugs like Oseltamivir are still available but are also in high demand [3][9][11]. - A pharmacy reported that Oseltamivir has been out of stock for over two weeks, with expectations for new supplies to arrive soon, while "速福达" is not expected to be restocked [9][11]. Hospital Preference - Parents prefer hospitals for flu treatment over pharmacies, as they trust clinical doctors more. The original manufacturers of "速福达" and Oseltamivir are ensuring a broad supply to hospitals across the country [10][11]. - Clinical demand for children's flu medications is increasing, with doctors noting that while there are no supply issues for Oseltamivir and Mabalaoshuwei, delivery disruptions can occur due to high demand [11][12]. Drug Efficacy and Usage - Oseltamivir is suitable for children aged 1 year and older, while Mabalaoshuwei is effective for children aged 5 to 12, with the latter being a single-dose oral medication, making it more convenient for parents [11][13]. - The latest guidelines indicate that flu medications are essential for treatment, as common cold medications do not replace antiviral drugs [12][13]. Market Dynamics - The market for children's single-dose flu medications is expected to become more competitive as several domestic pharmaceutical companies are developing similar products, which may challenge the current dominance of "速福达" [16][17]. - Recent approvals for new antiviral drugs targeting children are underway, with a focus on single-dose formulations, which could expand treatment options for pediatric patients [16][17].

Core Insights - The article discusses the rising demand for flu medications in China, particularly due to an early flu season in 2025, with a significant increase in orders for antiviral drugs [5][6]. - The market for flu medications is projected to exceed 100 billion yuan, driven by both traditional and innovative drugs [9][10]. - New flu medications are being developed with a focus on single-dose treatments, which are more convenient than traditional multi-day regimens [8][14]. Market Trends - The flu season in 2025 is expected to peak earlier than usual, leading to a surge in demand for flu medications [5]. - Orders for flu antiviral drugs have reportedly increased by over 100% in major northern cities [5]. - The introduction of several new flu medications has diversified consumer choices, moving away from the previously dominant Oseltamivir [5][10]. Product Development - A number of new flu medications are set to be launched in 2025, including products from various pharmaceutical companies targeting both A and B strains of the flu [7][15]. - The new medications are designed to be taken once for the entire course of treatment, contrasting with older medications that require multiple doses over several days [8][14]. - The pricing of new flu medications is significantly higher than traditional options, with some priced nearly ten times more than Oseltamivir [8][17]. Competitive Landscape - The flu medication market is characterized by competition between established drugs like Oseltamivir and new entrants with innovative mechanisms [12][16]. - The sales of Oseltamivir reached 9.8 billion yuan in 2023, maintaining its position as the leading flu medication [11]. - New medications are facing challenges in market penetration due to their higher prices and the need for consumer education on their benefits [18][19]. Consumer Behavior - There is a growing awareness among consumers about the differences between flu and common cold, leading to increased demand for effective flu treatments [10]. - Younger consumers are more inclined to choose newer, more convenient medications, while older populations tend to stick with traditional options [18]. - The market for flu medications is expected to evolve as more companies enter the space and as pricing becomes more competitive over the next few years [18][19].

Core Viewpoint - Health元 is transitioning from a "research investment phase" to a "value realization phase" in its innovative drug development, with significant progress in multiple core products, particularly the flu treatment drug, Marpapsavir, which is expected to be launched in 2024 [2][5] Financial Performance - In the first three quarters of 2025, Health元 achieved operating revenue of 11.478 billion yuan and a net profit of 1.091 billion yuan, with basic earnings per share of 0.6 yuan [1] Innovation Pipeline - The company has a robust innovation pipeline with over 20 first-class innovative drugs, 10 of which have entered critical phases beyond Phase II, indicating a well-structured pipeline matrix [3] - Marpapsavir, a novel drug for treating influenza, has completed Phase III clinical trials and is set to submit for market approval in August 2024, showcasing its unique advantages in rapid efficacy and single-dose administration [2][3] R&D System - Health元 has established a comprehensive R&D system focusing on respiratory, digestive, mental health, and assisted reproduction fields, creating a closed-loop process from early target exploration to clinical development and commercialization [3] - The company has increased R&D investment by 15% year-on-year in the first half of 2025, emphasizing clinical advancement of innovative drugs and core technology upgrades [3] Sustainable Development - The company maintains a healthy cash flow supported by stable contributions from mature businesses, allowing for continued investment in R&D while ensuring financial health [4] - Since 2020, Health元 has completed a share repurchase plan totaling 3.2 billion yuan, with a dividend payout of 0.20 yuan per share for the 2024 fiscal year, reflecting a commitment to shareholder returns [4] Future Outlook - Health元 aims to accelerate the market launch of core products like Marpapsavir and deepen its comprehensive R&D layout, reinforcing its technological advantages in key therapeutic areas [5]